Sandu [SANDUPHQ] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
Sandu
BSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sandu wins in 11 metrics, Sun Pharma Advanced wins in 6 metrics, with 0 ties. Sandu appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sandu | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.23 | -13.34 | Sun Pharma Advanced |
| Price-to-Book Ratio | 1.11 | -21.04 | Sun Pharma Advanced |
| Debt-to-Equity Ratio | 1.14 | -1.24 | Sun Pharma Advanced |
| PEG Ratio | N/A | 0.29 | N/A |
| EV/EBITDA | 15.29 | -16.99 | Sun Pharma Advanced |
| Profit Margin (TTM) | 2.41% | -53.22% | Sandu |
| Operating Margin (TTM) | 2.08% | -568.05% | Sandu |
| EBITDA Margin (TTM) | 2.08% | N/A | N/A |
| Return on Equity | 3.69% | 157.88% | Sun Pharma Advanced |
| Return on Assets (TTM) | 2.78% | -102.08% | Sandu |
| Free Cash Flow (TTM) | $104,000 | $-3.71B | Sandu |
| Dividend Yield | 1.61% | N/A | N/A |
| 1-Year Return | -18.34% | -34.25% | Sandu |
| Price-to-Sales Ratio (TTM) | 0.70 | 70.46 | Sandu |
| Enterprise Value | $447.85M | $48.18B | Sun Pharma Advanced |
| EV/Revenue Ratio | 0.67 | 74.59 | Sandu |
| Gross Profit Margin (TTM) | 58.93% | -10.68% | Sandu |
| Revenue per Share (TTM) | $69 | $2 | Sandu |
| Earnings per Share (Diluted) | $1.60 | $-9.19 | Sandu |
| Beta (Stock Volatility) | 0.20 | 0.31 | Sandu |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sandu vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sandu | 0.99% | 1.15% | -2.58% | -8.65% | -9.30% | -14.10% |
| Sun Pharma Advanced | 2.40% | -3.92% | -13.01% | -6.93% | -0.76% | -30.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sandu | -18.34% | -29.59% | 100.71% | 60.97% | 213.07% | 33.07% |
| Sun Pharma Advanced | -34.25% | -41.92% | -22.97% | -66.04% | 46.46% | -51.75% |
Performance & Financial Health Analysis: Sandu vs Sun Pharma Advanced
| Metric | SANDUPHQ | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹467.30M | ₹45.51B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,296 | 286,063 |
| 90 Day Avg. Volume | 2,398 | 352,245 |
| Last Close | ₹48.85 | ₹143.61 |
| 52 Week Range | ₹43.75 - ₹69.50 | ₹109.30 - ₹241.00 |
| % from 52W High | -29.71% | -40.41% |
| All-Time High | ₹86.00 (Apr 25, 2022) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -43.20% | -83.59% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | -0.43% |
| Quarterly Earnings Growth | 0.34% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | -0.53% |
| Operating Margin (TTM) | 0.02% | -5.68% |
| Return on Equity (TTM) | 0.04% | 1.58% |
| Debt to Equity (MRQ) | 1.14 | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.77 | ₹-6.69 |
| Cash per Share (MRQ) | ₹2.73 | ₹0.06 |
| Operating Cash Flow (TTM) | ₹5.35M | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹15.52M | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.61% | N/A |
| Last 12-Month Dividend | ₹0.80 | N/A |
Valuation & Enterprise Metrics Analysis: Sandu vs Sun Pharma Advanced
| Metric | SANDUPHQ | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.23 | -13.34 |
| Forward P/E | N/A | 2.53 |
| PEG Ratio | N/A | 0.29 |
| Price to Sales (TTM) | 0.70 | 70.46 |
| Price to Book (MRQ) | 1.11 | -21.04 |
| Market Capitalization | ||
| Market Capitalization | ₹467.30M | ₹45.51B |
| Enterprise Value | ₹447.85M | ₹48.18B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.67 | 74.59 |
| Enterprise to EBITDA | 15.29 | -16.99 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.31 |
| Book Value per Share (MRQ) | ₹43.77 | ₹-6.69 |
Financial Statements Comparison: Sandu vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANDUPHQ | SPARC |
|---|---|---|
| Revenue/Sales | ₹140.69M | ₹96.40M |
| Cost of Goods Sold | ₹57.79M | ₹106.70M |
| Gross Profit | ₹82.91M | ₹-10.30M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.02M | ₹-547.60M |
| EBITDA | ₹5.20M | ₹-429.40M |
| Pre-Tax Income | ₹3.45M | ₹-518.10M |
| Income Tax | ₹159,000 | ₹600,000 |
| Net Income (Profit) | ₹3.29M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANDUPHQ | SPARC |
|---|---|---|
| Cash & Equivalents | ₹13.04M | ₹19.64M |
| Total Current Assets | ₹262.99M | ₹261.97M |
| Total Current Liabilities | ₹120.86M | ₹3.74B |
| Long-Term Debt | ₹4.19M | ₹1.07B |
| Total Shareholders Equity | ₹420.17M | ₹-2.17B |
| Retained Earnings | N/A | ₹-23.22B |
| Property, Plant & Equipment | ₹181.22M | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANDUPHQ | SPARC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANDUPHQ | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,296 | 286,063 |
| Average Daily Volume (90 Day) | 2,398 | 352,245 |
| Shares Outstanding | 9.66M | 324.52M |
| Float Shares | 3.45M | 91.74M |
| % Held by Insiders | 0.66% | 0.73% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Sandu vs Sun Pharma Advanced
| Metric | SANDUPHQ | SPARC |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | N/A |
| Last 12-Month Dividend Yield | 1.61% | N/A |
| 3-Year Avg Annual Dividend | ₹1.02 | N/A |
| 3-Year Avg Dividend Yield | 1.12% | N/A |
| 3-Year Total Dividends | ₹3.05 | N/A |
| Ex-Dividend Date | Sep 19, 2024 | N/A |